CAR Stock Recent News

ASTON MARTIN VALKYRIE HYPERCAR COMMISSIONED BY DANIEL RICCIARDO TO HIS PERSONAL SPECIFICATION | AUCTION TO TAKE PLACE ON 10 OCTOBER 2025 IN COLLABORATION WITH ZOUTE GRAND PRIX CAR WEEK ASTON MARTIN VALKYRIE HYPERCAR COMMISSIONED BY DANIEL RICCIARDO TO HIS PERSONAL SPECIFICATION | AUCTION TO TAKE PLACE ON 10 OCTOBER 2025 IN COLLABORATION WITH ZOUTE GRAND PRIX CAR WEEK

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .

Shares of Avis Budget Group (CAR -5.54%) coughed and sputtered like a stalling car on Hump Day, shedding almost 6% of their price across the trading session. That was almost entirely due to the news that its archrival had secured one of the strongest sales channels in online retail.

The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of novel treatments for autoimmune disorders, where cutting-edge cell therapies hold promise to transform patient care.

Avis Budget Group CAR shares are trading lower after BofA Securities analyst Federico Merendi downgraded the stock from Buy to Underperform and cut its price target from $120 to $113.

Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif. , Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in the ongoing Phase 1 clinical trial evaluating the Company's novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif. , Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 12,384,826 covering its chimeric antigen receptor-T cell (CAR-T) technology.

CAR plunges 22% after second-quarter 2025 earnings and revenues miss estimates despite a nearly 98% YTD surge in shares.

Shares of Avis Budget Group (CAR -14.80%) were moving in the wrong direction today after the rental car leader came up short in its second-quarter earnings report.